Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Relay Therapeutics, Inc.

Relay Therapeutics, Inc. (RLAY) Stock Overview

Explore Relay Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

RLAY●NASDAQ
HealthcareBiotechnology
$19.70
$1.04(5.01%)
U.S. Market opens in 15h 41m

Relay Therapeutics, Inc. (RLAY)

Meyka AI Score

Z

Key Financials

Market Cap4.3B
P/E Ratio-13.14
EPS (TTM)$-1.57
ROE-0.42%
Fundamental Analysis

AI Price Forecasts

1 Month$20.73
3 Months$23.42
1 Year Target$21.29

RLAY Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Relay Therapeutics, Inc. (NASDAQ: RLAY) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Relay Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of RLAY on the NASDAQ shows an RSI of 51.28, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $21.29 for the NASDAQ listing.

Key metrics behind Relay Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -13.14 and a market capitalization of 4.3B. Combined with our AI analysis, these give both institutional and retail investors a clear view of RLAY on the NASDAQ.

Price Performance (NASDAQ: RLAY)

1-Day Change
-5.01%
5-Day Change
0.41%
1-Month Change
2.71%
3-Month Change
51.31%
6-Month Change
126.44%
Year-to-Date (YTD) Change
132.86%
1-Year Change
479.41%
3-Year Change
84.63%
5-Year Change
-37.52%
All-Time (Max) Change
-43.79%

Contact Information

https://www.relaytx.com
617 370 8837
60 Hampshire Street, Cambridge, MA, 02139

Company Facts

1,930 Employees
IPO DateJul 16, 2020
CountryUS
Actively Trading

Frequently Asked Questions